Spain Opioid-Induced Constipation Treatment Market

Spain Opioid-Induced Constipation Treatment Market

Opioid consumption in Spain has increased by 84% from 2008 to 2015, moving from 7.25 Defined Daily Doses/1000 inhabitants/day in 2008 to 13.31

2021-06-30

Growing prevalence of opioid induced constipation

Opioid consumption in Spain has increased by 84% from 2008 to 2015, moving from 7.25 Defined Daily Doses/1000 inhabitants/day in 2008 to 13.31 Defined Daily Doses/1000 inhabitants/day in 2015. Although opioids are highly efficacious for the treatment of acute and chronic pain, they can also cause a number of significant side effects. One of the most commonly reported side effects of opioid use is opioid induced constipation. Spain ranks fourth in the EU in the use of opioid analgesics with a prevalence rate of 0.07%. High prevalence of opioid drugs lead to higher prevalence of opioid induced constipation. In patients on chronic opioid therapy, the degree of opioid induced constipation can be quite severe and debilitating. According to Journal of Pain and Symptom Management, in 2018, around 30% of the population of Spain who were prescribed opioid drugs experienced constipation due to drug consumption. Hence, with rising prevalence of opioid-induced constipation in Spain, the demand for its treatment is increasing, thus leading to growth of the market

Recent drug approvals and robust pipeline

New pharmacological treatments are emerging at a rapid rate for treatment of opioid induced constipation PAMORAs (Peripherally acting mu-opioid receptor antagonists) are becoming more practical as treatment options. Recent approvals are emerging in tablet form compared to earlier subcutaneous injections. Few of the drugs have gained recent approval for the treatment of opioid induced constipation are Naldemedine which is manufactured by Shionogi Inc. and got FDA and EMA approval in 2017 and 2019, respectively. In the US market, Shionogi Inc. has partnered with Purdue Pharma in a joint venture for US commercialization of Symproic (Naldemedine) in 2017. In June 2019, Shionogi and Ferrer announced an exclusive promotion agreement for RIZMOIC® (naldemedine) in Spain for the treatment of opioid-induced constipation (OIC) in adult patients previously treated with a laxative. The late stage pipeline for OIC also seems to be promising with multiple potential drug candidates including – axelopran by. Theravance Biopharma that has completed Phase 2 successfully, naloxone, dolcanatide, and a combination of oxycodone and naloxone. Robust pipeline and recent drug approvals is anticipated to fuel the market in the forecast period.

Rising Consumption of Opioids for Chronic Pain

Opioids are the most effective analgesics for severe pain and the mainstay of acute and terminal cancer pain treatments. According to National Health and Wellness Survey of 2010, An estimated 6.10 million (17.25%) of the adult population of Spain reported experienced chronic pain in the surveyed year. Of these 11.69% experienced severe pain, 64.17% moderate pain and 24.14% mild pain. Daily pain was experienced by 6.95% of the population. This leads to an increase in the prescription of opioids increased by 8.2% in Spain.

According to European Monitoring Centre for Drugs and Drug Addiction, in 2019, 68,297 people in Spain were high risk opioid users. According to WHO, Since 1999, Spain has been one of the countries with the highest levels of opioid prescription coverage in the world. Methadone is the most commonly prescribed opioid agonist in Europe; it is used in 75% of patients. There is a rise in the number of cancer cases in Spain. According to Spanish Society of Medical Oncology, there is a rise of 15% in the number of cases in Spain from 2012 to 2017. Cancer patients start opioid treatment during their curative treatment, and if they develop chronic pain, the opioid treatment is continued. Hence, the increasing consumption of opioids for chronic pain in Spain is driving the growth of the opioid-induced constipation market.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com

Found it interesting?

Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866

We have 5000+ marketing reports and serve across 130+ countries